Payment overview · 2025
General Payments
$118.41
7 reported records · 3 companies
Healthcare provider profile · identity verified
John Gregory Bohlen, MD
Allopathic & Osteopathic Physicians|Family Medicine · CIRCLEVILLE, OH · NPI 1689665242
Verified facts
What the public records show
CMS Open Payments records show John Gregory Bohlen, MD received $118.41 in general payments during 2025 across 7 reported records.
AstraZeneca Pharmaceuticals LP accounted for 41.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $49.31 | 41.6% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $36.92 | 31.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $32.18 | 27.2% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $118.41 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $36.92 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $33.47 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $32.18 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 331 | 88 |
| Lisinopril | Lisinopril | 279 | 71 |
| Omeprazole | Omeprazole | 220 | 57 |
| Alprazolam | Alprazolam | 185 | 26 |
| Amlodipine Besylate | Amlodipine Besylate | 185 | 50 |
| Levothyroxine Sodium | Levothyroxine Sodium | 182 | 46 |
| Lorazepam | Lorazepam | 171 | 33 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 161 | 20 |
| Metformin Hcl | Metformin Hcl | 156 | 45 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 154 | 25 |
| Simvastatin | Simvastatin | 152 | 41 |
| Eliquis | Apixaban | 145 | 21 |
| Losartan Potassium | Losartan Potassium | 145 | 36 |
| Gabapentin | Gabapentin | 141 | 41 |
| Tramadol Hcl | Tramadol Hcl | 141 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 133 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 132 | 33 |
| Diclofenac Sodium | Diclofenac Sodium | 121 | 45 |
| Furosemide | Furosemide | 120 | 38 |
| Famotidine | Famotidine | 118 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 108 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 104 | 30 |
| Oxycodone Hcl | Oxycodone Hcl | 104 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 92 | 30 |
| Celecoxib | Celecoxib | 90 | 19 |
| Atenolol | Atenolol | 85 | 27 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 81 | 26 |
| Carvedilol | Carvedilol | 79 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 77 | 64 |
| Potassium Chloride | Potassium Chloride | 77 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 76 | 25 |
| Finasteride | Finasteride | 76 | 20 |
| Sertraline Hcl | Sertraline Hcl | 70 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 69 | 31 |
| Montelukast Sodium | Montelukast Sodium | 62 | 15 |
| Prednisone | Prednisone | 61 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 59 | 20 |
| Allopurinol | Allopurinol | 58 | 16 |
| Azithromycin | Azithromycin | 58 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | 18 |
| Glimepiride | Glimepiride | 56 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 50 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | 14 |
| Warfarin Sodium | Warfarin Sodium | 47 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 44 | 15 |
| Fluconazole | Fluconazole | 43 | 23 |
| Meloxicam | Meloxicam | 43 | 11 |
| Clonazepam | Clonazepam | 42 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 41 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 40 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 40 | 30 |
| Glyburide | Glyburide | 39 | 12 |
| Farxiga | Dapagliflozin Propanediol | 38 | suppressed |
| Diazepam | Diazepam | 36 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 36 | suppressed |
| Ozempic | Semaglutide | 36 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 33 | suppressed |
| Carisoprodol | Carisoprodol | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 27 |
| Spironolactone | Spironolactone | 32 | 11 |
| Cephalexin | Cephalexin | 31 | 22 |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | suppressed |
| Ibuprofen | Ibuprofen | 30 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 29 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 29 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 28 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 28 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Jardiance | Empagliflozin | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Methadone Hcl | Methadone Hcl | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 16 |
| Glipizide | Glipizide | 23 | suppressed |
| Torsemide | Torsemide | 23 | suppressed |
| Mupirocin | Mupirocin | 22 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 18 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 15 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 14 | suppressed |
| Clobazam | Clobazam | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Movantik | Naloxegol Oxalate | 14 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $118.41 · 7 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Cologuard Collection Kit, FARXIGA, Kerendia | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error